Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib(® )versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]

BACKGROUND: Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list. Transarterial chemoembolization (TACE) is used as bridging therapy with highly variable response rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, K, Glimm, H, Radeleff, B, Richter, G, Heining, C, Schenkel, I, Zahlten-Hinguranage, A, Schirrmacher, P, Schmidt, J, Büchler, MW, Jaeger, D, von Kalle, C, Schemmer, P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630329/
https://www.ncbi.nlm.nih.gov/pubmed/19036146
http://dx.doi.org/10.1186/1471-2407-8-349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630329/
https://www.ncbi.nlm.nih.gov/pubmed/19036146
http://dx.doi.org/10.1186/1471-2407-8-349

Ejemplares similares